Clinical bottom line
Circulating tumor DNA (ctDNA) analysis is an emerging tool with potential to guide treatment adaptation in advanced ovarian cancer by providing real-time insights into tumor dynamics and molecular alterations. Current evidence suggests that ctDNA levels and specific genomic or epigenetic markers detected in plasma may correlate with treatment response, disease progression, and prognosis. However, clinical implementation remains investigational, with limited prospective data validating ctDNA-guided treatment changes in ovarian cancer. Careful integration of ctDNA monitoring alongside established clinical and radiologic assessments may enhance personalized therapy strategies, but further validation in well-designed clinical trials is warranted before routine use.
What the evidence shows
Ovarian cancer is characterized by frequent molecular heterogeneity and acquired resistance to chemotherapy, underscoring the need for dynamic biomarkers to inform treatment decisions. Circulating tumor DNA, shed into the bloodstream by tumor cells, offers a minimally invasive means to monitor tumor burden and detect actionable genomic alterations (Cheng et al., 2017). A meta-analysis by Lu et al. (2021) demonstrated that higher ctDNA levels in ovarian cancer patients are associated with poorer prognosis, supporting its potential as a prognostic biomarker.
Specific epigenetic modifications detectable in ctDNA, such as BRCA1 promoter hypermethylation, have been correlated with improved survival outcomes, suggesting a role in patient stratification (2021 reviews). These findings indicate that ctDNA can reflect biologically relevant tumor characteristics that may influence treatment sensitivity.
While ctDNA-guided treatment adaptation has been explored in other malignancies such as non-small cell lung cancer and esophageal cancer, where early changes in ctDNA levels predicted response and resistance (Russo et al., 2022; Default Digital Object Group, 2026), analogous prospective data in ovarian cancer remain sparse. The principle of using ctDNA kinetics to tailor therapy—escalating, switching, or de-escalating treatment based on molecular response—is promising but not yet established in ovarian cancer clinical practice.
Caveats and uncertainty
Several challenges limit the current clinical utility of ctDNA-guided treatment adaptation in advanced ovarian cancer. First, ctDNA detection sensitivity varies with tumor burden and shedding rates, which can be low in some patients, leading to false negatives (Cheng et al., 2017). Second, standardized assays and thresholds for actionable ctDNA changes are lacking, complicating interpretation and comparison across studies.
The prognostic associations of ctDNA markers such as BRCA1 methylation require further validation in larger, prospective cohorts to confirm reproducibility and clinical relevance (2021 reviews). Moreover, the heterogeneity of ovarian cancer subtypes and treatment regimens necessitates subtype-specific evaluation of ctDNA utility.
Importantly, no large randomized trials have yet demonstrated that ctDNA-guided treatment adaptation improves survival or quality of life in ovarian cancer patients. Thus, the approach remains hypothesis-generating and should not replace established clinical and radiologic monitoring.
How this may change practice
If validated, ctDNA-guided treatment adaptation could enable more precise and timely modifications to therapy in advanced ovarian cancer, potentially improving outcomes by detecting resistance earlier and avoiding ineffective treatments. For example, rising ctDNA levels or emergence of resistance mutations could prompt earlier switch to alternative regimens or enrollment in clinical trials.
Integration of ctDNA analysis may also facilitate personalized maintenance strategies, such as selecting patients for PARP inhibitors based on BRCA1 methylation status or other epigenetic markers. Additionally, ctDNA could serve as a complementary tool to imaging and CA-125 monitoring, particularly in ambiguous cases.
Clinicians should remain aware of ongoing research and emerging evidence, considering ctDNA testing within multidisciplinary discussions and clinical trial contexts. Until robust prospective data are available, ctDNA-guided treatment adaptation should be viewed as an investigational approach warranting further study.